Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3427 in HFrEF patients with renal impairment
NCT06611423Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Primary completion
- Aug 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AZD3427 in heart failure with reduced ejection fraction (HFrEF) (4 arms), sponsored by AstraZeneca. Primary endpoint: Volumetric fraction of the renal cortex with increased perfusion at 8 days. Started Oct 2024; status: terminated.
02
Drugs
AZD3427
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT06611423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611423.